Cargando…

Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer

BACKGROUND: Mutations in the KRAS gene can be detected in about 70–90% of pancreatic cancer (PC) cases. Whether these mutations have a prognostic or predictive value remains elusive. Furthermore, the clinical relevance of the extended RAS (KRAS+NRAS) mutational status is unclear in PC. METHODS: We p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haas, Michael, Ormanns, Steffen, Baechmann, Sibylle, Remold, Anna, Kruger, Stephan, Westphalen, Christoph B, Siveke, Jens T, Wenzel, Patrick, Schlitter, Anna Melissa, Esposito, Irene, Quietzsch, Detlef, Clemens, Michael R, Kettner, Erika, Laubender, Ruediger P, Jung, Andreas, Kirchner, Thomas, Boeck, Stefan, Heinemann, Volker
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Genetics & Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520094/ https://www.ncbi.nlm.nih.gov/pubmed/28449008 http://dx.doi.org/10.1038/bjc.2017.115

Ejemplares similares

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
por: Ormanns, Steffen, et al.
Publicado: (2016)

Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research
por: Baechmann, Sibylle, et al.
Publicado: (2017)

The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy
por: Ormanns, Steffen, et al.
Publicado: (2017)

Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult
por: Boeck, S, et al.
Publicado: (2014)

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
por: Ormanns, Steffen, et al.
Publicado: (2014)

Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2020)

Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2021)

Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel
por: Sams, L., et al.
Publicado: (2021)

Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers
por: Dorman, Klara, et al.
Publicado: (2022)

TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer
por: Guenther, Michael, et al.
Publicado: (2023)

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer
por: Heinemann, V, et al.
Publicado: (2013)

Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
por: Kruger, S.F., et al.
Publicado: (2022)

Automated data analytics workflow for stability experiments based on regression analysis
por: Geistanger, Andrea, et al.
Publicado: (2022)

Definition of Microscopic Tumor Clearance (R0) in Pancreatic Cancer Resections
por: Schlitter, Anna Melissa, et al.
Publicado: (2010)

Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting
por: Sultova, Elena, et al.
Publicado: (2021)

Multiparametric 18F–FDG PET/MR follow-up in a patient with autoimmune pancreatitis
por: Rauscher, Isabel, et al.
Publicado: (2017)

Epithelial-Mesenchymal Transition Induces Endoplasmic-Reticulum-Stress Response in Human Colorectal Tumor Cells
por: Zeindl-Eberhart, Evelyn, et al.
Publicado: (2014)

Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma
por: Sun, Na, et al.
Publicado: (2021)

NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU
por: Sultova, Elena, et al.
Publicado: (2020)

Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer
por: Guenther, Michael, et al.
Publicado: (2022)

Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective
por: Weiss, L., et al.
Publicado: (2023)

Therapeutic management of neuro-oncologic patients - potential relevance of CSF liquid biopsy
por: von Baumgarten, Louisa, et al.
Publicado: (2020)

Projections of cancer incidence and cancer‐related deaths in Germany by 2020 and 2030
por: Quante, Anne S., et al.
Publicado: (2016)

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich(LMU) Molecular Tumor Board
por: Dorman, Klara, et al.
Publicado: (2023)

WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear β-Catenin depend on active PI3K signaling
por: Ormanns, Steffen, et al.
Publicado: (2014)

Advances in cancer immunotherapy 2019 – latest trends
por: Kruger, Stephan, et al.
Publicado: (2019)

Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study
por: Westphalen, C. Benedikt, et al.
Publicado: (2020)

Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials
por: Stahler, Arndt, et al.
Publicado: (2020)

Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy
por: Heinrich, Kathrin, et al.
Publicado: (2023)

Perspective of α(v)β(6)-Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions
por: Steiger, Katja, et al.
Publicado: (2017)

Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype
por: Liffers, Sven-Thorsten, et al.
Publicado: (2023)

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
por: Boeck, S, et al.
Publicado: (2013)

Mutations in the WTX - gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers
por: Scheel, Silvio K, et al.
Publicado: (2010)

A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich
por: Zhang, Danmei, et al.
Publicado: (2023)

Proposal: on the possible production of 1.) superheavy elements and 2.) unknown spontaneously fissioning activities a la Pontecorvo in the interaction of high-energy protons with Thorium
por: Brandt, R, et al.
Publicado: (1971)

Proposal: the possible production of superheavy elements in the interaction of high-energy protons with Tantalum
por: Brandt, R, et al.
Publicado: (1971)

The impact of sarcopenia on overall survival in patients with pan-RAS wild-type colorectal liver metastasis receiving hepatectomy
por: Yang, Yao-Ren, et al.
Publicado: (2023)

Homeopatía y lesiones deportivas : Obra de consulta y guía
por: Laubender, Eberhart

Altered expression of Bcl-2, c-Myc, H-Ras, K-Ras, and N-Ras does not influence the course of mycosis fungoides
por: Maj, Joanna, et al.
Publicado: (2013)

Reply to: The definition of locally advanced pancreatic cancer
por: Boeck, S, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_cns8lip8thldcoev73tnconu3b